The Board of Directors of Alkem Laboratories Limited, in their meeting held on 28th May 2026, approved the standalone and consolidated audited financial results for the quarter and financial year ended 31st March 2026. Additionally, the Board recommended a final dividend of ₹10 per equity share for the financial year ended 31st March 2026, subject to shareholder approval at the upcoming Annual General Meeting scheduled for 27th August 2026. The financial results analysis is as follows:

Alkem Laboratories Limited is a prominent Indian pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company operates globally with a diverse portfolio and maintains a significant presence in international markets through its various subsidiaries. For the quarter ended 31st March 2026, the company reported a consolidated revenue from operations of ₹36,033.2 million, compared to ₹37,368.2 million in the previous quarter and ₹31,437.5 million in the corresponding quarter of the previous year. The consolidated profit for the period stood at ₹2,511.1 million, down from ₹6,530.3 million in the previous quarter and ₹3,223.9 million in the corresponding quarter of the last year. The standalone financial results indicated a revenue from operations of ₹22,584.4 million for the quarter ended 31st March 2026. The company’s financial performance was influenced by exceptional items, including provisions for impairment and impact from revised labour code regulations.